- Study: Type 2 diabetes market competition heats up amid disease rate increase
- Sam's Club donates $1.25 million to expand YMCA health, wellness initiatives; retailer offers diabetes screenings
- Report: Sugar accounts for 17% of normal U.S. diet as Type 2 diabetes accounts for $500 billion in global healthcare spending
- Most people managing diabetes interested in weight-loss programs
- Cardinal Health invites independent pharmacy owners to ‘discover new horizons’ at RBC 2013
MOUNTAIN VIEW, Calif. — Patients taking a drug used for weight loss were able to reduce their chances of developing Type 2 diabetes, according to a new study.
According to data from a 475-patient study published in the journal Diabetes Care, Vivus' Qsymia (phentermine and topiramate) reduced the annualized incidence rate of Type 2 diabetes by up to 78.7% in high-risk, overweight or obese patients with prediabetes or metabolic syndrome. Prediabetes is a condition in which a person has elevated blood sugar and a high risk of developing Type 2 diabetes.
"These data demonstrate that medically assisted weight loss is highly effective in preventing progression to diabetes in an at-risk population, and underscores the observation that 10% weight loss achieves beneficial effects on metabolism and risk factors in patients with prediabetes and metabolic syndrome," University of Alabama nutrition sciences department chairman and study lead author Timothy Garvey said.